Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 2464

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 5
Chunk 2464
---

     -  
     -  
     -  
     627,154 
  
    Conversion of working capital loan into Series A preferred stock 
     1,605  
     1,555,000  
     -  
     -  
     -  
     -  
     -  
     1,555,000 
  
    Issuance of Series A shares sold to investors, net 
     7,854  
     6,755,698  
     -  
     -  
     (856,663) 
     -  
     -  
     5,899,035 
  
    Issuance of Series A Preferred Warrants 
     -  
     -  
     -  
     -  
     2,000,000  
     (2,000,000) 
     -  
     - 
  
    Issuance of common shares to Keystone Capital LLC for equity line of credit 
     -  
     -  
     1,191  
     -  
     633,345  
     -  
     -  
     633,345 
  
    Opening Equity at February 14, 2024 (Successor) 
     10,089  
    $8,937,852  
     145,318  
    $15  
    $53,899,871  
    $(2,000,000) 
    $(63,185,641) 
    $(2,347,903)

F-15

NOTE 4 – NET LOSS PER SHARE OF COMMON
STOCK

The accounting standards
require the presentation of both basic and diluted earnings per share on the face of the statements of operations. The Company’s
basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the
period. If there are dilutive securities, diluted income per share is computed by including common stock equivalents which includes shares
issuable upon the exercise of stock options into shares of common stock, exercise of preferred warrants into shares of preferred stock,
and conversion of preferred stock into shares of common stock, net of any shares assumed to have been purchased with the proceeds, using
the treasury stock method. In periods for which the Company reports a